Pipeline Lundbeck preps for key bexicaserin data around year-end PharmaphorumLundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.NeuroscienceRead full story pharminent July 20, 2026 (Last updated: July 20, 2026) Pharmaphorum Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Samsung Biologics to acquire PolyPeptide in $1.81bn cash dealNext: Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics Related Stories Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026 Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
